Month: March 2012

Study – Fumarate Decreases Heart Attack Damage in Mice

[et_pb_section fb_built=”1″ _builder_version=”3.0.47″][et_pb_row _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”0|0px|27px|0px”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]In a recently published paper ‘Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway’ by Houman Ashrafian and colleagues is published in the journal …

Read MoreStudy – Fumarate Decreases Heart Attack Damage in Mice

Article Review: Nrf2, Guardian of Healthspan and Gatekeeper of Species Longevity?

There are so many interesting articles on Pubmed regarding Nrf2, but this one gives an excellent summary of what NRF2 activation can do for the body. Entitled: “Nrf2, a Guardian of Healthspan and Gatekeeper of Species Longevity.” Sanjay Gupta in …

Read MoreArticle Review: Nrf2, Guardian of Healthspan and Gatekeeper of Species Longevity?

Nrf2 Drug Submitted for FDA approval for Multiple Sclerosis (MS)

UPDATE April 2013 Biogen’s BG-12 has been approved by the FDA and is now marketed under the name Tecfidera. Google News reported 28 Feb 2012 that Biogen Idec has submitted for FDA approval for new drug to treat Multiple Sclerosis. …

Read MoreNrf2 Drug Submitted for FDA approval for Multiple Sclerosis (MS)